Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Medtronic scoffs at St. Jude Medical’s claims that its Enlightn renal denervation system lowers blood pressure faster than Medtronic’s Symplicity, calling them “interesting” but merely “hypothesis-generating.”
A rare but deadly genetic mutation that prevents the body from absorbing protein can be set off by weight loss surgery.
The U.S. Justice Dept. closes its years-long criminal and civil investigation into Medtronic’s controversial Infuse bone growth protein.